Genmab — Oktober 2016
-
-
Tak Bud og Solsen. Har også gravet dette uddybende link frem: http://www.nejm.org/doi/suppl/10.1056/NEJMc1605684/suppl_file/nejmc1605684_appendix.pdf
-
Det postede Solsen kan jeg se.
-
Relapse of natural killer (NK) cell–T-cell neoplasms in the leukemic phase in a patient who has received l-asparaginase–based combination therapy and undergone allogeneic hematopoietic-cell transplantation is generally fatal within days, and there is no known standard of care.
-
Tak igen.
-
-
We received the most FDA approvals from 2011 to 2016 as well as eight breakthrough therapy designations. For four consecutive years, we have been named the Innovation Leader by IDEA Pharma and became the partner of choice to the work of J&J innovation. And for the third consecutive year, Fortune Magazine ranked Janssen Pharmaceutical Companies of Johnson & Johnson #1 in the pharmaceutical category on its annual World's Most Admired Companies list.
-
De har endda sat robotten på.
-
Så må JnJ satse på noget andet.
http://medwatch.dk/Medicinal___Biotek/article9087420.ece -
Tror nok vi skal få nogle gode nyheder de næste par måneder. Det er super spændende at være inde i Genmab. Og tak for alle de nyttige informationer man får her på chatten. Det er herligt.
-
God morgen.
-
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind